Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of clinical laboratories, life sciences and intellectual property through the development of unique diagnostic platform technologies that provide numerous advantages over previous standards. A global company, Enzo Biochem utilizes cross-functional teams to develop and deploy products, systems and services that meet the ever-changing and rapidly growing needs of health care today and into the future. Underpinning Enzo Biochem's products and technologies is a broad and deep intellectual property portfolio, with patent coverage across a number of key enabling technologies.

Company profile
Ticker
ENZ
Exchange
Website
CEO
Elazar Rabbani
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Enzo Clinical Labs, Inc. • Enzo Life Sciences, Inc. • Enzo Therapeutics, Inc. • Enzo Realty LLC • Enzo Realty II, LLC ...
IRS number
132866202
ENZ stock data
News
Enzo Biochem To Launch Monkeypox Testing Services This Week
11 Aug 22
Enzo Biochem Q3 EPS $(0.10) Down From $0.04 YoY, Sales $26.20M Down From $32.80M YoY
9 Jun 22
Earnings Scheduled For June 9, 2022
9 Jun 22
The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More
5 Jun 22
12 Health Care Stocks Moving In Friday's Pre-Market Session
3 Jun 22
Press releases
Enzo Biochem Appoints Matthew Kupferberg as General Counsel
3 Aug 22
Enzo Biochem Reports Third Quarter Fiscal 2022 Results and Provides Leadership and Corporate Updates Including Engagement of Jefferies as Financial Advisor
9 Jun 22
UPDATE -- Enzo Biochem to Report Third Quarter 2022 Financial Results and Business Update on Thursday, June 9th
6 Jun 22
Enzo Biochem to Report Third Quarter 2022 Financial Results and Business Update on Thursday, June 9th
2 Jun 22
Calendar
9 Jun 22
16 Aug 22
31 Jul 23
Financial summary
Quarter (USD) | Apr 22 | Jan 22 | Oct 21 | Jul 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jul 21 | Jul 20 | Jul 19 | Jul 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 32.13M | 32.13M | 32.13M | 32.13M | 32.13M | 32.13M |
Cash burn (monthly) | (no burn) | (no burn) | 1.62M | 1.12M | 282.33K | 617.67K |
Cash used (since last report) | n/a | n/a | 5.78M | 3.99M | 1.01M | 2.21M |
Cash remaining | n/a | n/a | 26.35M | 28.14M | 31.12M | 29.92M |
Runway (months of cash) | n/a | n/a | 16.3 | 25.2 | 110.2 | 48.4 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Jul 22 | Kara Cannon | Common Stock, $0.01 Par Value | Buy | Acquire P | No | No | 2.42 | 2,500 | 6.05K | 2,500 |
12 Jul 22 | Radoff Bradley Louis | Common Stock, $0.01 Par Value | Buy | Acquire P | No | No | 2.27 | 12,500 | 28.38K | 4,194,663 |
12 Jul 22 | Radoff Bradley Louis | Common Stock, $0.01 Par Value | Grant | Acquire A | No | No | 0 | 41,666 | 0 | 4,236,329 |
12 Jul 22 | Mary Tagliaferri | Common Stock, $0.01 Par Value | Grant | Acquire A | No | No | 0 | 41,666 | 0 | 80,729 |
12 Jul 22 | Ian B. Walters | Common Stock, $0.01 Par Value | Grant | Acquire A | No | No | 0 | 41,666 | 0 | 80,729 |
Institutional ownership, Q1 2022
37.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 50 |
Opened positions | 3 |
Closed positions | 14 |
Increased positions | 12 |
Reduced positions | 13 |
13F shares | Current |
---|---|
Total value | 65.1M |
Total shares | 21.72M |
Total puts | 30.1K |
Total calls | 55.7K |
Total put/call ratio | 0.5 |
Largest owners | Shares | Value |
---|---|---|
Harbert Discovery Fund | 5.18M | $17.03M |
Renaissance Technologies | 3.01M | $8.73M |
Roumell Asset Management | 2.39M | $6.94M |
Vanguard | 1.77M | $5.14M |
Dimensional Fund Advisors | 1.59M | $4.62M |
BLK Blackrock | 1.54M | $4.47M |
VIEX Capital Advisors | 1.44M | $4.16M |
Fuller & Thaler Asset Management | 951.24K | $2.76M |
Boothbay Fund Management | 539.95K | $1.57M |
Potomac Capital Management | 496.81K | $1.44M |
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
consumed, cumulative, home, HRSA, independent, prevalence, requisition, responded, RSU, stipulation, volatility, Walter
Removed:
automatic, automatically, began, begin, Charter, delayed, extended, falsely, letter, ongoing, opposition, planned, Proposed, repayment, reply, scheduled, significance, stated, submit, Supermajority, unrealized, Vote
Financial reports
Current reports
8-K/A
Material Modifications to Rights of Security Holders
6 May 22
8-K
Material Modifications to Rights of Security Holders
27 Apr 22
8-K
Submission of Matters to a Vote of Security Holders
8 Apr 22
8-K
Submission of Matters to a Vote of Security Holders
31 Mar 22
8-K
Enzo Biochem Announces Appointments of David Bench and Kara Cannon to New Executive Management Positions
30 Mar 22
8-K
Amendments to Articles of Incorporation or Bylaws
18 Mar 22
8-K
Departure of Directors or Certain Officers
7 Mar 22
8-K
Departure of Directors or Certain Officers
21 Jan 22
8-K
Hamid Erfanian and Bradley Radoff Appointed to Enzo Biochem’s Board of Directors
4 Jan 22
8-K
Departure of Directors or Certain Officers
18 Oct 21
Registration and prospectus
S-8
Registration of securities for employees
9 Nov 21
S-8
Registration of securities for employees
15 Jan 21
S-8
Registration of securities for employees
6 Mar 20
S-8
Registration of securities for employees
12 Aug 18
S-3/A
Shelf registration (amended)
27 Oct 16
424B5
Prospectus supplement for primary offering
30 Dec 14
S-8
Registration of securities for employees
24 Jun 14
S-3
Shelf registration
31 Jul 13
Proxies
DEFA14A
Additional proxy soliciting materials
6 Apr 22
DEFA14A
Additional proxy soliciting materials
1 Apr 22
DEF 14A
Definitive proxy
28 Feb 22
PRER14A
Preliminary revised proxy
18 Feb 22
PRE 14A
Preliminary proxy
6 Jan 22
PREC14A
Preliminary proxy with contested solicitation
19 Nov 21
DFAN14A
Additional proxy materials by non-management
25 Oct 21
DFAN14A
Additional proxy materials by non-management
19 Oct 21
DFAN14A
Additional proxy materials by non-management
5 Jan 21
DFAN14A
Additional proxy materials by non-management
31 Dec 20
Other
UPLOAD
Letter from SEC
28 Nov 21
UPLOAD
Letter from SEC
21 Jan 21
CORRESP
Correspondence with SEC
29 Dec 20
CORRESP
Correspondence with SEC
21 Dec 20
UPLOAD
Letter from SEC
16 Dec 20
UPLOAD
Letter from SEC
5 Mar 20
UPLOAD
Letter from SEC
13 Feb 20
CORRESP
Correspondence with SEC
10 Feb 20
UPLOAD
Letter from SEC
10 Feb 20
UPLOAD
Letter from SEC
19 Nov 19
Ownership
4
ENZO BIOCHEM / Kara Cannon ownership change
19 Jul 22
4
ENZO BIOCHEM / MARY TAGLIAFERRI ownership change
14 Jul 22
4
ENZO BIOCHEM / Ian B. Walters ownership change
14 Jul 22
4
ENZO BIOCHEM / Bradley Louis Radoff ownership change
14 Jul 22
4
ENZO BIOCHEM / Bradley Louis Radoff ownership change
13 Jul 22
4
ENZO BIOCHEM / Bradley Louis Radoff ownership change
6 Jul 22
11-K
Annual report of employee stock purchases
24 Jun 22
4
ENZO BIOCHEM / Hamid Erfanian ownership change
17 Jun 22
4
ENZO BIOCHEM / Bradley Louis Radoff ownership change
16 Jun 22
4
ENZO BIOCHEM / David Bench ownership change
15 Jun 22
Patents
Utility
Assays for Detecting Modified Compounds
3 Feb 22
Provided are methods and compositions which are useful for separating, isolating, detecting, and quantifying compounds of interest which have been modified chemically, enzymatically or catalytically from other compounds which have not been so modified.
Utility
Pharmaceutical Compositions and Methods Targeting WNT Pathway Proteins
27 Jan 22
Provided is a composition comprising a peptide comprising amino acids and/or amino acid analogs comprising a continuous sequence of a sclerostin fragment comprising Tyr43 or Tyr213.
Utility
Immunomodulatory Pharmaceutical Compositions Including a Synthetic Peptide and Transforming Growth Factor Beta
27 Jan 22
The invention provides immunomodulatory pharmaceutical compositions that include a synthetic peptide and one or more immune tolerance enhancers.
Utility
Fluorescence Quencher Polymer Conjugates and Uses Thereof
27 Jan 22
The invention provides chemical conjugates comprising a plurality of fluorescence quenching moieties conjugated to polymer and the use of such conjugates to quench the emission of fluorescence from emitters including macromolecular fluorescent emitters such as phycoerythrin.
Utility
Assays for detecting modified compounds
23 Nov 21
Provided are methods and compositions which are useful for separating, isolating, detecting, and quantifying compounds of interest which have been modified chemically, enzymatically or catalytically from other compounds which have not been so modified.
Transcripts
2022 Q3
Earnings call transcript
10 Jun 22
2022 Q2
Earnings call transcript
15 Mar 22
2022 Q1
Earnings call transcript
16 Dec 21
2021 Q3
Earnings call transcript
10 Jun 21
2021 Q2
Earnings call transcript
16 Mar 21
2021 Q1
Earnings call transcript
10 Dec 20
2020 Q4
Earnings call transcript
13 Oct 20
2020 Q3
Earnings call transcript
8 Jun 20
2020 Q1
Earnings call transcript
10 Dec 19
2019 Q4
Earnings call transcript
15 Oct 19
Reddit threads
Daily Discussion Thread - June 9th, 2022
9 Jun 22
Daily Discussion Thread - June 8th, 2022
8 Jun 22
Daily Discussion Thread - June 7th, 2022
7 Jun 22
Daily Discussion Thread - June 6th, 2022
6 Jun 22
Daily Discussion Thread - March 14th, 2022
14 Mar 22
Daily Discussion Thread - March 11th, 2022
11 Mar 22
Daily Discussion Thread - December 15th, 2021
15 Dec 21
Daily Discussion Thread - December 14th, 2021
14 Dec 21
Daily Discussion Thread - December 13th, 2021
13 Dec 21
Daily Discussion Thread - December 6th, 2021
6 Dec 21